Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070283
Filing Date
2025-05-13
Accepted
2025-05-13 16:03:22
Documents
72
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q svra-20250331.htm   iXBRL 10-Q 1500237
2 EX-3.1 svra-ex3_1.htm EX-3.1 62111
3 EX-10.1 svra-ex10_1.htm EX-10.1 918177
4 EX-31.1 svra-ex31_1.htm EX-31.1 16596
5 EX-31.2 svra-ex31_2.htm EX-31.2 16597
6 EX-32.1 svra-ex32_1.htm EX-32.1 12573
7 GRAPHIC img199934909_0.jpg GRAPHIC 11906
  Complete submission text file 0000950170-25-070283.txt   8225159

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT svra-20250331.xsd EX-101.SCH 956091
74 EXTRACTED XBRL INSTANCE DOCUMENT svra-20250331_htm.xml XML 1304688
Mailing Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746
Business Address 6836 BEE CAVE ROAD BUILDING 3, SUITE 201 AUSTIN TX 78746 51285113796
Savara Inc (Filer) CIK: 0001160308 (see all company filings)

EIN.: 841318182 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-32157 | Film No.: 25939877
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)